Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504010 · ClinicalTrials.gov registry record · Phase 1

The Role of Arnica on Muscle Pain Following Eccentric Exercise

A Phase 1 study of Exercise and Muscles, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 1
Development phase
55
Enrollment target
1
Study location

NCT00504010: Completed Phase 1 study of Exercise and Muscles, sponsored by The University of Texas Health Science Center, Houston.

NCT00504010 is a Phase 1 study of Exercise and Muscles that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 55 participants, below the 8,910-participant average among 57 other Exercise trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504010, a Phase 1 study of Exercise and Muscles, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 1
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

Arnica in a topical gel formulation will be compared to a placebo to determine whether it decreases muscle soreness following leg exercise when applied to the legs.

Interventions

  • DRUG Arnica Montana
  • DRUG placebo cream

Study Locations (1)

Texas

  • Memorial Family Medicine - Houston

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2007-08
Est. Completion 2008-09
Phase Phase 1

What the finished NCT00504010 record still lists

NCT00504010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 8,910-participant average among 57 other Exercise trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Exercise appearing as the primary indexed condition, and to 2 interventions - of which Arnica Montana is the first listed.

NCT00504010 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00504010 about?

NCT00504010 is a clinical study titled "The Role of Arnica on Muscle Pain Following Eccentric Exercise". Arnica in a topical gel formulation will be compared to a placebo to determine whether it decreases muscle soreness following leg exercise when applied to the legs.

What is the current status of trial NCT00504010?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2007-08. Estimated completion is 2008-09.

What conditions does trial NCT00504010 study?

This clinical trial studies the following conditions: Exercise, Muscles, Arnica.

What interventions are being tested in trial NCT00504010?

The interventions under investigation include: Arnica Montana (DRUG), placebo cream (DRUG).

Who is sponsoring clinical trial NCT00504010?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00504010 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Exercise

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00504010's enrollment target sits among peer trials

55 28th of 57 higher than 30 of 57 other Exercise trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Exercise trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00504010, the US trial registry maintained by the National Library of Medicine. NCT00504010 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.